BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bionomics Limited (BMICY.PK) Extends Contract of CEO and Managing Director Deborah Rathjen


8/8/2008 11:51:27 AM

Adelaide, Australia: Bionomics Limited (ASX: BNO) today announced the extension of the employment contract of Dr Deborah Rathjen, as CEO and Managing Director until 7 August 2011.

Dr Peter Jonson, Chairman of Bionomics said: The Board is pleased to have extended Dr. Deborah Rathjen’s contract, she is a respected member of our team and in the broader biotechnology and pharmaceutical community. She has successfully led Bionomics through a number of company changing events and achieved significant uplift in share value.”

Dr Rathjen has been instrumental in transforming Bionomics from a genomics company to a fully integrated drug discovery company with clinical stage compounds, through a strategy combing merger and acquisition activity and organic growth. This is best evidenced in Dr. Rathjen’s ability to secure and oversee the integrations of the lliad and Neurofit acquisitions.

The strength of Bionomics’ pipeline, which includes anti-cancer agent BNC105 and anxiolytic BNC210, reflects Dr. Rathjen’s commitment and persistence in the execution of Bionomics’ strategy.

Dr. Rathjen has also successfully led a number of significant drug discovery partnership deals for Bionomics. Recently, she secured a development and license agreement On Bionomics’ Multiple Sclerosis program with Merck Serono. In 2006 she successfully converted Bionomics’ 2002 co-development agreement with Genmab A/S covering angiogenesis drug targets to a licensing agreement which included an upfront payment development milestones and royalties on product sales. A preclinical milestone under the agreement was paid by Genmab earlier this year.

Dr Rathjen said: “Bionomics has a great team of experienced and highly motivated people focused on its success. We have a number of important milestones ahead which will continue to define Bionomics as a rising star and I feel privileged to continue at the helm.”

FOR FURTHER INFORMATION PLEASE CONTACT: Bionomics Limited Dr Deborah Rathjen CEO & Managing Director +618 8354 6101 / 0418 160 425 drathjen@bionomics.com.au Media Enquiries

Therese Minehan Buchan Consulting +612 9237 2800 / 0414 388 955 tminehan@bcg.com.au

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES